Study of the pharmacokinetics, pharmacodynamics, and safety of the biosimilar pembrolizumab RPH-075 compared to Keytruda® in patients with malignant neoplasms
Authors:
- I. А. PokataevIPI. А. Pokataev
- L. G. ZhukovaLZL. G. Zhukova
- D. L. StroyakovskyDSD. L. Stroyakovsky
- R. V. OrlovaROR. V. Orlova
- А. М. MudunovАMА. М. Mudunov
- М. В. PakМPМ. В. Pak
- Е. V. ZernovaЕZЕ. V. Zernova
- А. V. SobolevАSА. V. Sobolev
- А. S. MochalovaАMА. S. Mochalova
- B. Ya. AlekseevBAB. Ya. Alekseev
- М. I. SekachevaМ. I. Sekacheva
Open Access
- 15 March 2024
- journal article
- research article
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 14 (1) , 56-66
Abstract
Introduction: Pembrolizumab is a humanized monoclonal antibody selectively blocking the interaction between the PD-1 receptor and its ligands. The drug RPH-075 is a biosimilar to the original Keytruda®.Objective: To establish the equivalence of pharmacokinetic (PK) properties, as well as pharmacodynamic (PD) parameters, safety, and immunogenicity of the drug RPH-075 compared to Keytruda® in patients with malignant tumors.Materials and Methods: This multicenter double-blind randomized study included 90 patients with melanoma and non-small cell lung cancer who were randomized into two treatment groups (RPH-075 and Keytruda ®) in 1:1 ratio. In both groups, pembrolizumab was administered as monotherapy at a dose of 200 mg intravenously every 3 weeks until progression or intolerable toxicity. The primary aim of the study was to assess PK after the first administration. The primary endpoint for PK assessment was AUC(0–504), and for safety, it was the frequency of adverse events (AE). The decision on PK equivalence was planned to be made if the two-sided 90 % confidence interval (CI) for the geometric mean ratio of AUC(0–504) after a single administration of each drug would be within 80.00–125.00 %. Secondary endpoints included Cmax after the first administration, as well as the other PK, safety, and immunogenicity parameters. This study also assessed PK and PD parameters after multiple administrations, and a pilot efficacy assessment was planned.Results: This article presents the analysis of data from the first stage of the study (after the first drug administration with a 3‑week observation period). The data analysis was blinded, and the treatment groups were coded as A and B. The 90 % CI for the geometric mean ratio of AUC(0–504) after the administration of drug A to AUC(0–504) of drug B was 93.50–121.16 %, and for the ratio of B to A, it was 82.54–106.95 %. The obtained intervals met the specified equivalence limit of 80.00–125.00 %, allowing us to conclude that RPH-075 and original Keytruda® are PK equivalent. Both drugs demonstrated comparably high saturation of PD-1 receptors on CD4+ / CD8+ lymphocytes at the end of the first cycle (day 22). Binding antibodies to pembrolizumab were detected in 2 patients (one in each group) over the analyzed period, indicating comparably low immunogenicity for both drugs. Safety profile analysis during this period revealed 7 AEs in 4 patients in group A and 4 AEs in 3 patients in group B. The frequency of AEs did not significantly differ between the groups.Conclusions: PK, PD, immunogenicity, and safety parameters of the pembrolizumab biosimilar RPH-075 were equivalent to those of the original Keytruda®.Keywords
This publication has 13 references indexed in Scilit:
- Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjectsExpert Opinion on Investigational Drugs, 2020
- A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjectsCancer Chemotherapy and Pharmacology, 2020
- A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjectsExpert Opinion on Investigational Drugs, 2020
- A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteersCancer Chemotherapy and Pharmacology, 2020
- Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy SubjectsAdvances in Therapy, 2020
- Evaluation of dosing strategy for pembrolizumab for oncology indicationsJournal for ImmunoTherapy of Cancer, 2017
- Immune checkpoint inhibition in ovarian cancerInternational Immunology, 2016
- Cancer immunotherapy comes of ageNature, 2011
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct MechanismsMolecular and Cellular Biology, 2005